GlassScriptPhysician profile
Trisha Hutson
NPI 1568701662
$6,477.21
in general payments reported to CMS, 2019-2025
30 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,282 · 2022: $1,347 · 2023: $1,259 · 2024: $1,417 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,848.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,511.38 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $965.13 | 2021-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $781.71 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $452.63 | 2022-2025 | |
| Lilly USA, LLC | $432.07 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $403.79 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $189.48 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $183.75 | 2021-2023 | Trintellix |
| Amgen INC. | $154.59 | 2021-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $145.16 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $137.73 | 2023-2024 | Gemtesa |
| Esperion Therapeutics, INC. | $125.29 | 2021-2025 | Nexletol |
| Astellas Pharma US INC | $116.00 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $100.10 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $98.39 | 2023-2024 | Trelegy Ellipta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $89.86 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.51 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $77.91 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $68.90 | 2021 | |
| Shield Therapeutics INC | $68.43 | 2023-2024 | Accrufer |
| Sanofi-Aventis U.S. LLC | $55.35 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $53.50 | 2023 | Xarelto, Spravato |
| Merck Sharp & Dohme LLC | $44.91 | 2021 | |
| Corcept Therapeutics | $41.56 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.44 | 2025 | Caplyta |
| Dexcom, INC. | $16.84 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $16.25 | 2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $16.07 | 2021 | |
| Axsome Therapeutics, INC. | $15.53 | 2025 | Auvelity |
| Eisai INC. | $14.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trisha Hutson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.